FDA Releases Final Guidance on Prescription Drug Companion Apps and Software

The U.S. Food and Drug Administration issued final guidance on Tuesday establishing regulatory recommendations for how pharmaceutical companies develop, distribute, and label mobile apps and software used alongside prescription medications.

The new framework clarifies when companion software content is subject to agency submission requirements, when an app must be included in a drug's official prescribing information, and what documentation companies must submit when distributing app content.

Under the guidance, the FDA distinguishes between two primary categories of companion software:

• Apps connected to medical devices: Software paired with a medical device, such as an app connected to an asthma inhaler, generally should be described on the drug's official prescribing label due to its direct role in administering the medication.
• Standalone apps: Programs such as symptom trackers, dose reminders, or health coaching tools must appear on the official prescribing label if the manufacturer demonstrates the software is essential for safe and effective use or provides a meaningful clinical benefit. In most other instances, content displayed by standalone companion apps will be regulated as promotional labeling, aligned with standard drug advertising rules.

According to the FDA, the guidance aims to provide regulatory certainty for developers while ensuring that health management tools offer accurate, evidence-based information to patients and healthcare providers.

Source